Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Catalent, Inc.
"One of the facilities that experienced productivity issues is the Company’s gene therapy manufacturing site located in Harmans, Maryland near the BWI airport (“BWI”), where the Company’s plans to increase capacity for a customer’s product during the third quarter in order to ramp production was slower than expected. During this ramp-up, certain operational challenges, including those related to the initial deployment of a new enterprise resource planning (ERP) system at BWI, significantly reduced the expected revenue in the third fiscal quarter associated with the site, and will also impact revenue previously expected in the fourth quarter...
None of these issues is expected to adversely impact the quality or commercial launch quantities of any product made at BWI in light of, among other things, the level of “bright stock” on hand. However, revenue from the unproduced batches cannot be made up for in this fiscal year due to manufacturing capacity constraints. The Company expects to recover related revenue in the second half of calendar year 2023 (the first half of the Company’s 2024 fiscal year).
In the third fiscal quarter, the Company also experienced productivity challenges and higher-than-expected costs at its drug product and drug substance manufacturing facilities located in Bloomington, Indiana and Brussels, Belgium, where the Company was unable to achieve anticipated productivity levels and associated revenue due in part to the continued need to implement enhancements to its operational and engineering controls following regulatory inspections that occurred earlier in the fiscal year. While these issues are also expected to affect the Company’s fiscal fourth quarter to end on June 30, 2023, productivity levels in Bloomington are expected to be restored to previously forecast levels in that quarter. As with BWI, the Company does not expect to make up for the lost production at Bloomington until after the close of the current fiscal year.
After conducting an internal review of the Company’s manufacturing operations, the Company has taken a number of measures at BWI, Bloomington, and Brussels, including both management and operational changes, to address the root causes of the issues identified at each..."
All of this should be good for CDMO.
what about Thermofisher or Novo Nordisk, they can't make enough Wegovy at $350 a vial.
I remember
I want to remind people we closed at 14.59 on 1/29/2021 and 11.86 on 12/31/2020.
I'll take it
don't you mean over the $1B mark?
precedent not president. I guess you had the current politics on your mind.
mine's 25 and I am not that hopeful
David Carbone mentioned in the Columbus Dispatch today. Using a $3 million Pelotonia grant researcheers at OSU wil conduct a statewide research study
that will genetically test
more than 2,000 advanced
lung-cancer patients in an
effort to treat their illness
with targeted therapy.
The three-year Beating
Lung Cancer in Ohio initiative,
to begin in March,
will recruit patients newly
diagnosed with Stage 4 nonsmall-
cell lung cancer. They
will receive free testing for
300 genes, while also being
tested for a PD-L1 marker
used to help select certain
immunotherapy treatments.It often is
diagnosed in a metastatic,
or fourth, advanced state,
said Dr. David Carbone, one
of the lead researchers on
the study and director of the
Thoracic Cancer Center at
The James.
“Getting patients on the
right treatment — the first
time — is absolutely critical,”
Carbone said in a statement.
“We know advanced
genomic testing can help
us identify the patients
most likely to benefit from
a targeted therapy, which
is oftentimes a pill and
well-tolerated, vs. traditional
chemotherapies not
specifically targeted to that
patient’s genetic mutations.
I had asked John Columbia with Alexander Capital about how the trial was designed and he said this.
Here's an example of a drug that failed in its first phase 3 trial and went on to get approved to treat several cancer indications. Oh yeah, it also has about 60 billion in sales.
Cover of time magazine: Inside the brutally selective, hugely expensive, life saving trials of immunotherapy
http://time.com/4270414/in-the-latest-issue-64/
Does anyone know how quickly these people look at events, once a week? once a month?
I wish we never visit the 1.20s again.
In the movie The Constant Gardener the bad chemical company was Peregrine also. And of course there is Peregrine Financial. People like the falcon.
Can you fix your date to 2015. I think June 2014 is over.
Well it made it to Cleveland now.
If you are going to the ASM are to going to reveal your identity?
There is an issue with the high compensation but that didn't outweigh the other factors that I considered for this investment. It's not going to change and in the long run it's a non-factor.
If you want an investment without any issues you should consider buying treasury bonds.
Number one, there's nothing criminal going on here. Number two, they aren't sucking money out, they're funding operations. Yes, as a result they're diluting all shareholders. The thing is, management has warned us that dilution could happen so anyone buying shares is taking on that risk. There's a section in every 10K and 10Q that's titled "THE SALE OF SUBSTANTIAL SHARES OF OUR COMMON STOCK MAY DEPRESS OUR STOCK PRICE." that warns investors about this. The latest 10K goes on to say "In addition, we will need to raise substantial additional capital in the future to fund our operations, including our Phase III SUNRISE trial. If we raise additional funds by issuing equity securities, the market price of our securities may decline and our existing stockholders may experience significant dilution.". Don't blame management for this situation. If anything, blame yourself for buying shares and ignoring the obvious pitfalls.
Based on my research, I'm long PPHM. Based on your research, you're obviously short PPHM. That's fine with me but at the same time I'm not going to wish you luck with your investment. IMO, the world will be better off if PPHM and Bavi are successful.
PPHMVERYLONG, help me out here. I really can't agree with anything you said in this post. Maybe you can clear up some of these issues I have.
Since you take all of these predictions and forecasts to heart and then they ultimately go up in smoke resulting in a great deal of frustration to you, I have a suggestion that could help you out. Just sit tight with your investment in PPHM but stop reading this message board and ignore anything that management says.
You deserve a life without these burdens. Good luck with your new brighter future and I'm looking forward to hearing from you again when the share price is above 10 dollars.
You were too quick on that one.
What is the number we make it to 500 M market cap? And when do people stop calling this a penny stock?
It was hard to get any work done yesterday while watching the stock market.
40.8 percent will get cancer in their lifetime. About 2 out of 3 survive for 5 years at the present time. May Bavi help people to live longer healthier lives.
PPHM closed Sept 6, 2012 at 3.07 and opened Sept 7,2012 at 3.15. The high that day was 5.08 and close was 4.50 for a gain of 46%. The high of the day was a gain of 65% over the previous close. I hope this keeps filling that gap to 5.39 and beyond. Glta Pat on the back to my old man today.
High of 2013 was 2/13/2013 2.43. Great day today.
The math is fine. The share count three years ago was 67.8 million.
Why is that troubling?
You are asuming that all the preferred shares are going to be sold immediately. I don't think so.
I already addressed those frustrations of yours in my post 156989. So again, why don't I ever see you post anything positive on the up days?